Alirocumab (anti-PCSK9)

Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.

Alirocumab (anti-PCSK9)

Click to purchase the isotype control of Alirocumab (anti-PCSK9)

Purity & Quality Control

Batch: A204701 Purity: 98% Protein concentration: 4.3mg/ml Endotoxin Level: <1 EU/mg
98

Choose Selective PCSK9 Inhibitors

Biological Activity

Description Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.

Product Details

CAS No. 1245916-14-6
Molecular Weight 150 kDa
Isotype human IGg1, κ
Application Alirocumab (anti-PCSK9)
Source CHO
Purification Protein G
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Alirocumab (anti-PCSK9) | Alirocumab (anti-PCSK9) supplier | purchase Alirocumab (anti-PCSK9) | Alirocumab (anti-PCSK9) cost | Alirocumab (anti-PCSK9) manufacturer | order Alirocumab (anti-PCSK9) | Alirocumab (anti-PCSK9) distributor